



REMARKABLE SCIENCE. ENDURING PERFORMANCE.™

Revance Therapeutics  
Investor Relations Department  
7555 Gateway Boulevard  
Newark, CA 94560  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: RVNC**


Last Trade:	27.93
Trade Time:	11:11 AM ET Apr 26, 2018
Change:	-0.42 <span style="color: red;">↓</span> (-1.472%)
Day Range	27.60 - 28.85
52-Week Range	18.43 - 37.45
Volume	142,911

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comp... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Apr 25, 2018*  
[Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018](#)
- Apr 24, 2018*  
[Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018](#)
- Apr 19, 2018*  
[Revance Investor Day Highlights New Neuroscience Indications in Development](#)
- Apr 2, 2018*  
[Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable](#)
- Mar 26, 2018*  
[Revance to Host Investor Day on April 19, 2018](#)

## Upcoming Events [\[ View all \]](#)

- May 8, 2018 4:30 PM ET*  
[Revance Therapeutics 2018 First Quarter Financial Results](#)

## Financials [\[ View all \]](#)

- [Fourth Quarter Financial Results](#)
- Mar 2, 2018*  
[Annual Report \(10-K\)](#)
- Mar 20, 2018*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)